| 生物活性 |
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin . Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC).
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 分子量 |
146.96 kDa
|
||||||||||||
| CAS号 |
1629760-28-6
|
||||||||||||
| 中文名称 |
Ladiratuzumab
|
||||||||||||
| 运输条件 |
Shipping with dry ice.
|
||||||||||||
| 储存方式 |
|
纯度： 99%
咨询热线：
400-881-9290
Data Sheet
